PROTAC 工程化蛋白/DNA 纳米抗原是癌症免疫治疗中树突状细胞疫苗的有效增强剂
PROTAC-Engineered Protein/DNA Nanoantigen is a Potent Booster for Dendritic Cell Vaccines in Cancer Immunotherapy.
树突状细胞（DC）疫苗在肿瘤免疫治疗中的疗效常因抗原交叉呈递（XPT）效率低下导致的免疫原性较弱而受到限制。
94.0分
★★★★★
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
免疫肿瘤学：靶点与治疗的新见解
英文原题：Immuno-Oncology: New Insights into Targets and Therapies.
研究概要
免疫治疗在肿瘤外科患者护理中的作用有望扩大，随着研究者和临床医生评估新的靶点和方法。
中文摘要
免疫治疗在肿瘤外科患者护理中的作用有望随着研究者和临床医生评估新靶点和新方法而不断扩大。目前正在进行的临床试验正在评估新的免疫检查点，包括淋巴细胞活化基因3、T细胞免疫受体与Ig和ITIM结构域，以及杀伤细胞Ig样受体2DL1/2L3。通过mRNA递送的疫苗在早期临床试验中已显示出令人振奋的结果，并有望扩大应用。研究性方法包括树突状细胞疫苗、肽疫苗、细胞因子疗法和细胞疗法。这些研究有可能彻底改变肿瘤外科患者的治疗管理，并促进手术切除后的持久治愈。
展开英文摘要原文
The role of immunotherapy in the care of surgical oncology patients promises to expand as investigators and clinicians evaluate new targets and approaches. Currently active clinical trials evaluate new immune checkpoints, including lymphocyte activation gene 3, T cell immunoreceptor with Ig and ITIM domains, and killer Ig-like receptor 2DL1/2L3. Vaccines delivered through mRNA have demonstrated exciting results in early clinical trials and hold promise for expanded application. Investigational approaches include dendritic cell vaccines, peptide vaccines, cytokines therapies, and cellular therapies. These studies have the potential to revolutionize the management of surgical oncology patients and promote durable cures following surgical resection.
论文信息
- 作者
- Schokrpur S、White MG、Roland CL、Patel SP
- 第一作者单位
- Division of Hematology/Oncology, Department of Medicine, University of California, San Diego, 3855 Health Sciences Drive, La Jolla, CA 92037, USA.United States
- 通讯作者单位
- Division of Hematology/Oncology, Department of Medicine, University of California, San Diego, 3855 Health Sciences Drive, La Jolla, CA 92037, USA. Electronic address: patel@ucsd.edu.United States
- 文献类型
- 综述 · 非美国政府资助研究
- 期刊
- Hematology/oncology clinics of North America2026 Oct
- 原文标识
- PubMed 42686326 · DOI 10.1016/j.hoc.2026.05.020